Polycystic ovary syndrome is one of the most common gynecological endocrine diseases in women. This article mainly discusses the etiology and pathogenesis of polycystic ovary syndrome from the two aspects of traditional Chinese medicine and western medicine, and focuses on the mechanism of action of Guishen Pill. The clinical efficacy of symptoms. Polycystic ovary syndrome (PCOS) is an endocrine disease that mostly occurs in women during adolescence and reproductive age. Patients are characterized by persistent anovulation and ovarian polycystic changes. The clinical manifestations include irregular menstruation, infertility, hirsutism, and acne, obesity, acanthosis nigricans [1]. Traditional Chinese medicine does not have this disease name. According to its clinical manifestations and characteristics, it belongs to "infertility", "oligomenorrhea" and "amenorrhea" [2]. While PCOS may also be associated with a variety of complications, including insulin resistance, type 2 diabetes, and psychiatric disorders, the cause remains unclear. There is relevant evidence that polycystic ovary syndrome and genetic factors, intrauterine factors and environmental factors, as well as epigenetic mechanisms [3]. 

Ziyin Ma, Lihong Zhu. Clinical experience of Guishen pill combined with Diane-35 in the treatment of polycystic ovary syndrome. International Journal of Frontiers in Medicine (2022), Vol. 4, Issue 9: 33-37. https://doi.org/10.25236/IJFM.2022.040907.

[1] RUAN X, LI M, MUECK A O. Why does polycystic ovary syndrome (PCOS) need Long-term management[J]. Curr Pharm Des, 2018, 24(39): 4685-4692

[2] Meng Zhaojing, Ge Jun, Hou Lihui. Analysis of polycystic ovary syndrome from the perspective of traditional Chinese and Western medicine [J]. Clinical Research of Traditional Chinese Medicine, 2013, 5(02): 85-86.

[3] Elisabet Stener-Victorin. Epigenetic and transgenerational transmission of polycystic ovary syndrome[J]. Current Opinion in Endocrine and Metabolic Research, 2020, 12: 72-77.

[4] Zuo Li, Fu Yajun. Advances in the etiology and treatment of polycystic ovary syndrome [J]. Chongqing Medicine, 2018, 47(09): 1247-1250.

[5] Tan Yong. Traditional Chinese Medicine and Gynecology [M] Beijing: China Traditional Chinese Medicine Press, 10th Edition, 2016, 84-92.

[6] Wang Yirong. Summary of Wang Xiuyun’s clinical experience in the treatment of polycystic ovary syndrome [J]. Liaoning Journal of Traditional Chinese Medicine, 2016, 43(6): 1160-1163.

[7] Chai Hailan, Chen Shoulong, Gao Renmei, et al. Guishen Pills mainly treat PCOS-induced ovulatory infertility and its effects on serum TGF-β1 and CTGF levels [J]. Shaanxi Traditional Chinese Medicine, 2017, 38(8): 1065-1067.

[8] Chai Hailan, Chen Shoulong, Gao Renmei, et al. Clinical study on the treatment of PCOS-induced ovulatory infertility with Guishen Pill and acupoint acupuncture [J]. Shaanxi Traditional Chinese Medicine, 2017, 38(11): 1542- 1544.

[9] Lu Yan, Wang Xiaoyun. The mechanism of network pharmacology of Guishen Pill in the treatment of polycystic ovary syndrome [J]. New Chinese Medicine and Clinical Pharmacology, 2021, 32(06): 825-833. DOI: 10.19378/j. issn.1003-9783.2021.06.011.

[10] YUAN K, ZHU Q, LU Q, et al. Quercetin alleviates rheumatoid arthritis by inhibiting neutrophil inflammatory activities[J]. J Nutr Biochem, 2020, 84:108454.

[11] WANG Y Y, CHANG CY, LIN SY, et al. Quercetin protects against cerebral ischemia/reperfusion and oxygen glucose deprivation/ reoxygenation neurotoxicity[J]. J Nutr Biochem, 2020, 83:108436.

[12] EID HM, HADDAD P S. The antidiabetic potential of quercetin: underlying mechanisms[J]. Curr Med Chem, 2017, 24(4): 355-364.

[13] ZENG H, GUO X, ZHOU F, et al. Quercetin alleviates ethanolinduced liver steatosis associated with improvement of lipophagy [J]. Food Chem Toxicol, 2019, 125: 21-28.

[14] NAM SY, JEONG HJ, KIM HM, Kaempferol impedes IL-32-induced monocyte-macrophage differentiation[J]. Chem Biol Interact, 2017, 274: 107-115.

[15] TORRES- VILLARREAL D, CAMACHO A, CASTRO H, et al. Anti-obesity effects of kaempferol by inhibiting adipogenesis and increasing lipolysis in 3T3- L1 cells[J]. J Physiol Biochem, 2019, 75(1): 83-88.

[16] MAHOBIYA A, SINGH TU, RUNGSUNG S, et al. Kaempferolinduces vasorelaxation via endothelium-independent pathways in rat isolated pulmonary artery [J]. Pharmacol Rep, 2018, 70(5): 863-874.

[17] IMRAN M, SALEHI B, SHARIFI-RAD J, et al. Kaempferol: a key emphasis to its anticancer potential[J]. Molecules, 2019, 24(12): 2277.

[18] HIDAYATHULLA S, SHAHAT AA, AHAMAD SR, et al. GC/MS analysis and characterization of 2- Hexadecen -1- ol and beta sitosterol from schimpera arabica extract for its bioactive potential as antioxidant and antimicrobial[J]. J Appl Microbiol, 2018, 124(5): 1082-1091.

[19] PONNULAKSHMI R, SHYAMALADEVI B, VIJAYALAKSHMI P, et al. In silico and in vivo analysis to identify the antidiabetic activity of beta sitosterol in adipose tissue of high fat diet and sucrose induced type- 2 diabetic experimental rats[J]. Toxicol Mech Methods, 2019, 29(4): 276-290.

[20] TURCK D, CASTENMILLER J, DE HENAUW S, et al. A combination of beta-sitosterol and beta-sitosterol glucoside and normal function of the immune system: evaluation of a health claim pursuant to article 13(5) of regulation (EC) No 1924/2006[J]. EFSA J, 2019,17(7):e5776.

[21] Shi Shuai, Liu Hong. Effects of Daying-35 and Yasmin on lipid metabolism, sex hormone levels and pregnancy outcomes in patients with obese polycystic ovary syndrome [J]. China Maternal and Child Health, 2018, 33(10): 2217-2221.

[22] Chen Min. Analysis of the effect of Diane-35 combined with ovulation induction in the treatment of infertility and pregnancy outcomes in polycystic ovary syndrome [J]. System Medicine, 2022, 7(08): 164-168. DOI: 10.19368 /j.cnki.2096-1782.2022.08.164.

[23] Arkhypkina TL, Lyubimova LP, Misiura KV, et al. The state of carbohydrate metabolism in patients with polycystic ovary syndrome[J]. Int J Endocrinol (Ukraine), 2017, 13(6): 407-414.

[24] Xu Xiaohang, Chen Yuanhui, Wang Qian, et al. New progress in the diagnosis and treatment of polycystic ovary syndrome [J]. International Journal of Health/Family Planning, 2015, 34(2): 160-164.